What if you could move beyond monitoring
to actively managing cancer?

At Personalis, we are transforming the active management of cancer through more personalized testing. Our assays combine tumor-and-normal profiling with proprietary algorithms to deliver the most advanced insights, even as cancer evolves over time. With our industry-leading products, you can detect recurrence at the earliest timepoints, confidently select therapies based on ultra-comprehensive genomic profiling, and enhance your biomarker strategy for drug development.

Recurrence is Personal

NeXT Personal™, built on a patented tumor-informed approach, delivers industry-leading 1-3 part per million sensitivity to reliably detect residual disease and recurrence at the earliest time points while simultaneously enabling therapeutic decision making through variant tracking.

Therapy Selection is Personal

NeXT Dx™ more accurately identifies somatic alterations to help inform actionable treatment decisions and clinical trial matching through personalized tumor-normal comprehensive genomic profiling.

Drug Development is Personal

ImmunoID NeXT® provides a multidimensional view of both the tumor and the complex interplay with the tumor microenvironment, delivering coverage-augmented exome and transcriptome data with advanced, specialized analytics for biomarker discovery.

It’s time for a new standard
that empowers you with the information you need
when you need it.